Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location.
about
The importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathyViral Vaccines and CTL ResponseConsensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cellsIntraepithelial γδ T cells remain increased in the duodenum of AIDS patients despite antiretroviral treatmentProspects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.Memory CD8+ T cell differentiationHIV-1 neuroimmunity in the era of antiretroviral therapy.Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responsesMicrodevices for examining immunological responses of single cells to HIVThe role of mTOR in memory CD8 T-cell differentiationIL-12 is required for mTOR regulation of memory CTLs during viral infection.Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection.New approaches to design HIV-1 T-cell vaccinesHIV vaccines: lessons learned and the way forward.Gp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosaProtective capacity of memory CD8+ T cells is dictated by antigen exposure history and nature of the infectionDurable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeysPathogen-induced inflammatory environment controls effector and memory CD8+ T cell differentiation.Mycobacterium tuberculosis infection interferes with HIV vaccination in miceRepetitive peptide boosting progressively enhances functional memory CTLsTLR agonists are highly effective at eliciting functional memory CTLs of effector memory phenotype in peptide immunization.Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors.An HIV-1 Mini Vaccine Induced Long-lived Cellular and Humoral Immune Responses.Splenic priming of virus-specific CD8 T cells following influenza virus infectionQuick to remember, slow to forget: rapid recall responses of memory CD8+ T cells.Diversity in T cell memory: an embarrassment of riches.Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors.Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases.Justification for the inclusion of Gag in HIV vaccine candidates.Environmental cues orchestrate regional immune surveillance and protection by pulmonary CTLs.Revealing the Complexity in CD8 T Cell Responses to Infection in Inbred C57B/6 versus Outbred Swiss Mice.Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination.
P2860
Q26859307-8B564BF9-6C9D-4133-BF81-1A9CF5AE0F04Q27491330-C09686B8-E237-475E-8470-3EB3FDEDFCB6Q28487823-6E369ACB-97A8-40D6-813E-82EC0D52ECE6Q28740478-4A76788F-A038-4A13-B44F-805DE946D334Q30375714-35618FEF-22DE-45D5-B647-36A98A190B19Q33720379-278D0081-9AEC-4181-ABE2-1C38970EAB30Q33733529-7902D9F2-626B-4E5A-91D7-F6A0C21F784BQ34055541-F6011445-1AD6-4AB0-9A82-EC57987BD776Q34065197-CAC2B8B9-6CB7-4658-B9F9-F7360BD6AFFFQ34120067-50ED514E-54CC-430B-8F59-552E66EC43BEQ34143415-5C1EDB39-D10C-4228-A9C8-51E21B1C9860Q34188729-2FC9760F-CFF7-4026-895D-273365B7BC79Q34274849-640D5A89-1E76-42CC-898D-A1F07E57AF6FQ34342558-39117029-6B61-4FB0-A00E-711E4D1B32D9Q34727695-62F42AB3-89F1-4A79-8EAC-CDB856C73442Q35012041-8D897709-4435-4153-BEFE-FE862EE507E5Q35363320-E8B9F667-103B-49CE-9C3A-83294AA7C433Q35523289-987C670A-7A5A-4E54-A17F-5EB6DC60C826Q36121878-818D9FE6-4DDE-4AD8-96A2-FC02A839FAA7Q36153446-042B9E49-A0CD-41A1-9089-DD861715EA01Q36539888-EA7D1B25-B08F-4355-8568-9C0E5779B1EBQ36559772-2FF10FDF-273E-4E05-84EE-682AD934FC81Q36625724-C8AB3791-1E0B-4658-8BA7-40327802ED70Q36760154-4B3262A7-2887-4942-B1D8-E3B45C26E0B5Q37661337-951ECDC5-5C41-4F1E-9389-AE50AD9DC130Q37671907-EF40B74C-9FD3-4B34-AF31-A6A41F3D7FB4Q37932525-26B3C9A2-6E3E-45F0-9CA7-D0179AEBED5DQ38164258-1A223118-DFCA-44B1-81A5-E19157629D21Q38662319-49A5FC38-9E57-47F5-ACA8-5BD5EC693B8AQ38869063-28F9546B-76A6-45F0-83DA-D12BF0DD87D3Q47094361-33302702-6B1E-4A38-AB6B-67F868763F88Q51890555-6B04B412-C651-4FF5-A475-EF0797B2CFEF
P2860
Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Developing an HIV cytotoxic T- ...... uantity, quality and location.
@en
Developing an HIV cytotoxic T- ...... uantity, quality and location.
@nl
type
label
Developing an HIV cytotoxic T- ...... uantity, quality and location.
@en
Developing an HIV cytotoxic T- ...... uantity, quality and location.
@nl
prefLabel
Developing an HIV cytotoxic T- ...... uantity, quality and location.
@en
Developing an HIV cytotoxic T- ...... uantity, quality and location.
@nl
P2860
P921
P1476
Developing an HIV cytotoxic T- ...... uantity, quality and location.
@en
P2093
D Masopust
P2860
P304
P356
10.1111/J.1365-2796.2008.02054.X
P407
P577
2009-01-01T00:00:00Z